Videos

Mahmoud Khaimi, MD, briefly discussed the launch of the iTrack Advance handheld device at the 2023 ASCRS annual meeting in San Diego.

Lisa Nijm, MD, discussed Preservative Freedom, a coalition that has been put together by Thea to help bring attention and bring awareness to creating preservative-free drops for all patients at the 2023 ASCRS annual meeting in San Diego.

Mitchell Jackson, MD, discussed laser scleral microporation from Ace Vision Group at the 2023 ASCRS annual meeting in San Diego.

Sam Garg, MD, discussed his paper on the 36-month outcomes for the Juvene modular intraocular lens at the 2023 ASCRS annual meeting in San Diego.

Warren Foust, chief operating officer of STAAR Surgical, discussed the company and looked toward the future at the 2023 ASCRS annual meeting in San Diego.

Brian Shafer, MD, discussed Fortisite and the ability to treat corneal ulcers at the 2023 ASCRS annual meeting in San Diego.

John Berdahl, MD, discussed the Aurion clinical trials of endothelial cell therapy injection at the 2023 ASCRS annual meeting in San Diego.

Daniel Chang, MD, discussed his paper on a study comparing TECNIS Symfony OptiBlue IOL with the TECNIS Symfony Legacy IOL at the 2023 ASCRS annual meeting in San Diego.

Rob Thornhill, CEO of Centricity Vision, discussed the FDA clearing of ZeptoLink at the 2023 ASCRS annual meeting in San Diego.

Anthony Wallace, Vice President and General Manager of the US Surgical Business at Bausch + Lomb, discussed the introduction of SeeLuma, a fully digital surgical visualization platform, and more at the 2023 ASCRS annual meeting in San Diego.

Patrick Herde, General Manager of Ophthalmology and Optometry at ModMed, discussed a retrospective on the company's 10-year anniversary 2023 ASCRS annual meeting in San Diego.

Denise M. Visco, MD, discussed her presentation on astigmatism management with a dual-pulse femtosecond laser called ALLY, from Lensar, at the 2023 ASCRS annual meeting in San Diego.

Edward Hu, MD, PhD, discussed his paper on the single surgeon retrospective comparative analysis of 517 eyes of two subgroups of routine cataract surgery at the 2023 ASCRS annual meeting in San Diego.

Zeba Syed, MD, from Wills Eye Hospital discussed their research on corneal swelling and dynamics during corneal collagen crosslinking at the 2023 ASCRS annual meeting in San Diego.

Sandor Palfi, Commercial Vice President of the Americas at Johnson & Johnson Vision discussed pipeline updates for the company including the ELITA femtosecond platform at the 2023 ASCRS annual meeting in San Diego.

Rob Weinstock, MD from the Eye Institute of West Florida presented on his experience working with the ALLY cataract femtosecond laser cataract system from LENSAR at the 2023 ASCRS annual meeting in San Diego.

Ophthalmology Times© met with Eva Liang at the 2023 ASCRS annual meeting in San Diego where she presented data on outcomes of the Rasch-scaled Catquest-9SF questionnaire before and after implantation of the enVista toric lens.

Jim Mazzo, executive chairman of Neurotech Pharmaceuticals, discussed the company's goal to slow down the progression of MacTel and their recent advancements at the ASCRS annual meeting in San Diego.

Lance Kugler, MD, recapped his presentation and findings on the safety of office-based cataract surgery with the Ophthalmology Times© team at the ASCRS annual meeting in San Diego.

Mark Baum, CEO of Harrow discussed the recent launch of Iheezo and other key updates from the company with the Ophthalmology Times© team at the ASCRS annual meeting in San Diego.

Ophthalmology Times© caught up with Alice Epitropoulos at the 2023 ASCRS annual meeting in San Diego. Among her presentations at the event, she shared data regarding the visual and refractive outcomes of aberration-free monofocal hydrophobic toric IOLs.

Ophthalmology Times© spoke with Greg Kunst about Aurion BioTech's 12-month data from their recent Escalón trial 2023 at the ASCRS annual meeting in San Diego.

Stephen Coleman from Coleman Vision in Albuquerque, New Mexico, spoke with the Ophthalmology Times© team discussed the long-term outcomes with LASIK using the iDesign 2.0 software.

Ophthalmology Times® spoke with Mitch Shultz, MD at ASCRS 2023 in San Diego about the a new FDA clinical trial for a device called StableVisc being launched on the market by Bausch + Lomb.

George Waring IV, MD met with the onsite Ophthalmology Times© team to share data from his presentation on the first in-human results for the OmniVu IOL system.

Ophthalmology Times© spoke with Richard Lewis, CMO of ViaLase at the 2023 ASCRS meeting in San Diego. There he gave out team the details of his presentation for the 2 year follow up of the first in-human study of Femtosecond Laser Image Guided High-Precision Trabeculotomy (FLigHT).

John Berdahl, MD sat down with David Hutton, Managing Editor, Ophthalmology Times®, to discuss his abstract on the Phase 3 trials of iDose TR, versus topical timolol at the ASCRS annual meeting in San Diego.